Your browser doesn't support javascript.
loading
Design, synthesis, X-ray studies, and biological evaluation of novel macrocyclic HIV-1 protease inhibitors involving the P1'-P2' ligands.
Ghosh, Arun K; Sean Fyvie, W; Brindisi, Margherita; Steffey, Melinda; Agniswamy, Johnson; Wang, Yuan-Fang; Aoki, Manabu; Amano, Masayuki; Weber, Irene T; Mitsuya, Hiroaki.
  • Ghosh AK; Department of Chemistry, Purdue University, West Lafayette, IN 47907, USA; Department of Medicinal Chemistry, Purdue University, West Lafayette, IN 47907, USA. Electronic address: akghosh@purdue.edu.
  • Sean Fyvie W; Department of Chemistry, Purdue University, West Lafayette, IN 47907, USA.
  • Brindisi M; Department of Chemistry, Purdue University, West Lafayette, IN 47907, USA.
  • Steffey M; Department of Chemistry, Purdue University, West Lafayette, IN 47907, USA.
  • Agniswamy J; Departments of Biology and Chemistry, Georgia State University, Atlanta, GA 30303, USA.
  • Wang YF; Departments of Biology and Chemistry, Georgia State University, Atlanta, GA 30303, USA.
  • Aoki M; Departments of Hematology and Infectious Diseases, Kumamoto University of Medicine, Kumamoto 860-8556, Japan.
  • Amano M; Departments of Hematology and Infectious Diseases, Kumamoto University of Medicine, Kumamoto 860-8556, Japan.
  • Weber IT; Departments of Biology and Chemistry, Georgia State University, Atlanta, GA 30303, USA.
  • Mitsuya H; Departments of Hematology and Infectious Diseases, Kumamoto University of Medicine, Kumamoto 860-8556, Japan; Experimental Retrovirology Section, HIV and AIDS Malignancy Branch National Cancer Institute, Bethesda, MD 20892, USA; Center for Clinical Sciences, National Center for Global Health and Med
Bioorg Med Chem Lett ; 27(21): 4925-4931, 2017 11 01.
Article en En | MEDLINE | ID: mdl-28958624
ABSTRACT
Design, synthesis, and evaluation of a new class of HIV-1 protease inhibitors containing diverse flexible macrocyclic P1'-P2' tethers are reported. Inhibitor 5a with a pyrrolidinone-derived macrocycle exhibited favorable enzyme inhibitory and antiviral activity (Ki=13.2nM, IC50=22nM). Further incorporation of heteroatoms in the macrocyclic skeleton provided macrocyclic inhibitors 5m and 5o. These compounds showed excellent HIV-1 protease inhibitory (Ki=62pM and 14pM, respectively) and antiviral activity (IC50=5.3nM and 2.0nM, respectively). Inhibitor 5o also remained highly potent against a DRV-resistant HIV-1 variant.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Diseño de Fármacos / Proteasa del VIH / Inhibidores de la Proteasa del VIH / Compuestos Macrocíclicos Idioma: En Año: 2017 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Diseño de Fármacos / Proteasa del VIH / Inhibidores de la Proteasa del VIH / Compuestos Macrocíclicos Idioma: En Año: 2017 Tipo del documento: Article